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Targeted detection of genetic alterations
reveal the prognostic impact of H3K27M
and MAPK pathway aberrations in
paediatric thalamic glioma
Scott Ryall1,2 , Rahul Krishnatry1,3, Anthony Arnoldo4, Pawel Buczkowicz1,4, Matthew Mistry1, Robert Siddaway1,
Cino Ling1, Sanja Pajovic1, Man Yu1, Joshua B. Rubin5, Juliette Hukin6, Paul Steinbok7, Ute Bartels3, Eric Bouffet3,
Uri Tabori1,3,8 and Cynthia Hawkins1,2,4,9*

Abstract
Paediatric brain tumours arising in the thalamus present significant diagnostic and therapeutic challenges to physicians
due to their sensitive midline location. As such, genetic analysis for biomarkers to aid in the diagnosis, prognosis and
treatment of these tumours is needed. Here, we identified 64 thalamic gliomas with clinical follow-up and characterized
targeted genomic alterations using newly optimized droplet digital and NanoString-based assays. The median age at
diagnosis was 9.25 years (range, 0.63–17.55) and median survival was 6.43 (range, 0.01–27.63) years. Our cohort
contained 42 and 22 tumours reviewed as low and high grade gliomas, respectively. Five (12 %) low grade and 11
(50 %) high grade gliomas were positive for the H3F3A/HIST1H3B K27M (H3K27M) mutation. Kaplan-Meier survival
analysis revealed significantly worse overall survival for patients harbouring the H3K27M mutation versus H3F3A/
HIST1H3B wild type (H3WT) samples (log-rank p < 0.0001) with a median survival of 1.02 vs. 9.12 years. Mitogen-activated
protein kinase (MAPK) pathway activation via BRAF or FGFR1 hotspot mutations or fusion events were detected in 44 %
of patients, and was associated with long-term survival in the absence of H3K27M (log-rank p < 0.0001). Multivariate
analysis demonstrated H3K27M status and high grade histology to be the most significant independent predictors of
poor overall survival with hazard ratios of 6.945 and 7.721 (p < 0.0001), respectively. In contrast, MAPK pathway activation
is a predictor of favourable patient outcome, although not independent of other clinical factors. Importantly, we show
that low grade malignancies may harbour H3K27M mutations and that these tumours show a dismal survival compared
to low grade H3WT cases. Our data strongly supports the inclusion of targeted genetic testing in childhood thalamic
tumours to most accurately stratify patients into appropriate risk groups.
Keywords: Thalamic glioma, Pediatric, H3K27M, MAPK, BRAF, Prognostic

Introduction
Brain tumours are the largest group of solid tumours
and the leading cause of tumour-related death in children [4]. In particular, tumours arising in midline
structures of the brain including the brainstem and
thalamus present significant challenges for physicians
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in regards to their therapeutic approach. At present,
tumours arising in the brainstem, known as diffuse
intrinsic pontine glioma (DIPG), have been extensively
investigated and stratified into disease subtypes [6, 20].
Whereas DIPG is heavily researched, thalamic tumours, accounting for approximately 5 % of all paediatric brain neoplasms, are largely unexplored [8–10,
14, 27, 28]. Currently, the outcome of patients with
thalamic tumours is predicted based on the histological grade and the potential for surgical resection
of the tumour. High grade tumours classified as
World Health Organization (WHO) grade III or IV
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are associated with worse clinical outcome as compared to grade I or II low grade tumours [23, 24].
Due to their precarious midline location and the vital
functions of the thalamus and nearby structures, these
tumours, particularly the diffuse gliomas, often cannot
be completely resected, which is associated with a
worse clinical outcome [2, 10, 22, 27]. Further, limited
resections also potentially lead to sampling related errors in histological grading due to small biopsy specimens [12, 26]. As such, there is a need to identify
genetic biomarkers to supplement histological grading
and extent of surgical resection to aid in the diagnosis and management of thalamic tumour cases.
Recent studies have identified several biomarkers
that aid in disease diagnosis and are important in
predicting patient outcome in childhood gliomas. Recurrent mutations in histone H3 in which lysine 27
is substituted for methionine (H3K27M) were first
described in patients with paediatric high grade glioma, primarily DIPG [20, 31, 33]. When correlated
to clinical outcome, the presence of H3K27M in
DIPG was associated with worse overall survival as
compared to those with wild type H3 (H3WT) status, regardless of the histology of the tumour [5, 20,
21]. Subsequent studies have identified H3K27M mutations in other high grade midline tumours, including those in the thalamus, but have not looked
directly at its impact on patient survival [5, 31, 33].
In addition to H3K27M, genetic aberrations affecting
the RAS-MAPK pathway including KIAA1549-BRAF
and other BRAF, RAF and FGFR fusion events, as
well as BRAF and FGFR1 point mutations have been
described primarily in hemispheric low grade gliomas
in adults and children [7, 18, 19, 30, 34]. KIAA1549BRAF fusions have previously been shown to be associated with better patient survival [3, 15] while
BRAFV600E has been linked to increased likelihood
of tumour progression and transformation in low
grade glioma [17, 25]. FGFR1 aberrations including
N546K and fusion events with TACC were reported
in low grade paediatric astrocytomas [18, 34] and
the former shown to be a negative prognostic
marker in a small cohort of grade I pilocytic astrocytomas [3]. However, thalamic gliomas are often
under-represented in glioma cohorts because their
midline location often means only a biopsy is performed and there is little tissue available to study.
Thus a comprehensive study of genetic markers and
their role relative to histologic and clinical risk factors has not been performed for thalamic glioma. To
address this limitation, we assembled a cohort of
concisely defined paediatric thalamic glioma. We investigated the diagnostic and prognostic roles of defined genetic, clinical and histologic markers.
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Materials and methods
Patient cohort

After institutional ethics board approval of the study, review of the pathology and oncology databases at the Toronto Hospital for Sick Children (SickKids) identified
101 patients diagnosed with thalamic glioma in the MRI
era (1986 to 2014). As SickKids is the only reference
center for children in a population of 5 million people,
no selection bias is expected, and this qualifies as a
population-based study. All cases were centrally
reviewed for pathological diagnosis and grading according to WHO criteria (CH) [23]. Where available, MRIs
were reviewed to confirm thalamic tumour origin (RK).
Twenty-three tumours originally identified as thalamic
were determined to not be central to or originating from
the thalamus but rather, involved the thalamus and were
excluded. Four cases were excluded due to bi-thalamic
involvement. Ten tumours were excluded due to insufficient material yielding a final cohort of 64 (Additional
file 1: Table S1). We further assembled an independent
trans-Canadian cohort as previously described [32]
which was used for validation purposes (Additional file 2:
Table S2).
DNA/RNA isolation

DNA was extracted from 5 to 10 10 μm thick scrolls of
formalin-fixed-paraffin-embedded (FFPE) tissue using
the MasterPure Complete DNA and RNA Purification
Kit (Epicentre, WI, USA) according to the manufacturer’s instructions with a modified proteinase K digestion in which incubation time was increased from 24 to
48 h. Total RNA was extracted from FFPE tissue with
the RNeasy FFPE extraction kit (QIAGEN, CA, USA)
using the manufacturer’s guidelines. RNA/DNA quality
was assessed based on 260/280 values obtained using
the NanoDrop 2000 (Thermo Scientific, DE, USA) and
samples between 1.7–1.9 and 1.9–2.0 were considered to
be of sufficient quality for DNA and RNA, respectively.
Samples were quantified using the Qubit Fluorometer
V2.0 (Thermo Scientific, DE, USA).
ddPCR mutation detection

The Bio-Rad (Hercules, CA, USA) QX200 ddPCR system was used to detect H3K27M (including H3F3A and
HIST1H3B/C due to sequence similarity), H3F3AG34V/R, BRAFV600E and FGFR1N546K mutations.
Droplet digital PCR (ddPCR) workflow was completed
as described [16]. Samples temporarily consisted of 1X
ddPCR Supermix for Probes (no dUTP) (Bio-Rad),
900nM of specific forward and reverse primers, 250nM
of specific mutant and wild type specific probe, and 10–
50 ng of genomic DNA depending on the quality. Each
reaction was mixed with 70 μl of Droplet Generation Oil
(Bio-Rad) and partitioned into a minimum of 10,000
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droplets, transferred to a 96-well plate and sealed prior
to PCR amplification. PCR amplification was completed
in a C1000 thermo cycler (Bio-Rad) with the following
cycling conditions: 1 x (95 °C for 10 min), 39 x (95 °C
for 30 s, 55 °C for 60 s, with 2 °C s-1 ramp rate), and 1 x
(98 °C for 10 min). Following amplification, fluorescent
intensity was measured with the QX200 Droplet Reader
(Bio-Rad) and data analysis performed with the QuantaSoft droplet reader software (Bio-Rad). All samples were
run in duplicate to ensure validity. Samples were considered positive if a minimum of 10 mutant droplet and
1 % mutant allele frequency were detected in both duplicate runs. This threshold was arbitrarily set and we report no false positive detection ever approaching this
defined threshold.
The ddPCR assay was fully optimized for clinical implementation. DNA loading concentration, PCR settings,
and reaction conditions were corrected to ensure sufficient probe separation for confident mutation identification (Additional file 3: Figure S1, Additional file 4:
Figure S2, and Additional file 5: Figure S3). A cohort of
clinical DIPG and high grade astrocytoma samples previously evaluated with whole exome sequencing (WES)
(Applied Biosystems SOLiD 5500xl) were used to compare methods [20]. ddPCR showed 100 % concordance
with WES calls from both fresh frozen and FFPE samples (Additional file 6: Table S3 and Additional file 7:
Table S4). Importantly, it must be noted that due to sequence similarity, the H3K27M droplet digital probe is
unable to distinguish between H3F3A and HIST1H3B/
C, and hence will detect a K27M mutation in any of the
aforementioned genes. Similar optimization procedures
were completed for H3G34V/R, BRAFV600E and
FGFR1N546K (data not shown). Assay sensitivity was
determined by serially diluting an H3K27M-positive
sample with normal DNA from 50 to 0.01 % MAF
(Additional file 8: Figure S4). The ddPCR assay was able
to accurately detect the mutation at allele frequencies as
low as 1 % in FFPE preserved samples in accordance with
the minimum detection limits described above.

expressed fusion. Data is viewed using a box plot and
the presence of an extreme outlier (3xIQR) indicate fusion expression.

NanoString fusion detection

ddPCR and NanoString assays were used to identify targeted mutations and fusions of interest based on their
previous association with paediatric glioma (Fig. 1). The
most recurrent hotspot mutation was H3K27M, identified in 16 (25 %) thalamic tumours tested. No H3G34R/
V mutations were observed as expected. BRAFV600E
mutations were present in 10 (16 %) cases, with 2 cooccurring with H3K27M mutations. KIAA1549-BRAF
fusion events including those involving exons 16;09,
16;11 and 15;09 in order of prevalence, were detected in
14 (39 %) of the 36 samples from which sufficient quality
RNA was obtained. These were mutually exclusive with
H3K27M, BRAFV600E and FGFR fusions/mutations.

Probes targeting the 33 most commonly reported fusions
in paediatric glioma (Additional file 9: Table S5) were
designed in collaboration with NanoString (WA, USA).
Five hundred nanograms of total RNA was added to the
nCounter Elements TagSet in hybridization buffer and
incubated at 67 °C for 20 h. The sample was processed
on the nCounter Preparation Station and the cartridge
scanned at 555 fields of view on the nCounter Digital
Analyzer. Raw counts were subjected to a technical
normalization using counts obtained for positive control
probe sets included in each run. The statistical outlier
detection method was used to detect the presence of an

Statistics

Statistical analysis was performed using SPSS v23 (IBM
Corporation) or GraphPad Prism 5 (La Jolla, CA, USA).
Overall survival was determined using the Kaplan–Meier
method and univariate assessments of Kaplan–Meier
plots were tested using log rank. p values <0.05 were
considered to be statistically significant. Multivariate
Cox proportional hazard models and significance based
on the Wald test (α = 0.05) were performed for multivariate analysis.

Results
Clinical characteristics of patients with thalamic glioma

Sixty-four patients treated at the Hospital for Sick
Children from 1986 to 2014 were identified as thalamic
tumour patients. Forty-two thalamic tumours were histologically diagnosed as low grade glioma (62 % grade I,
5 % grade II, and 33 % low grade glioma, NOS) whereas
the remaining 22 were diagnosed as high grade glioma
(41 % grade III, 50 % grade IV, and 9 % high grade,
NOS). Two (5 %) low grade gliomas later transformed to
high grade malignancies. Median age of diagnosis for
thalamic glioma patients was 9.25 years (range, 0.63–
17.55 years). Forty-one (64 %) patients received surgical
resection (5 partial, 25 subtotal and 11 gross total resection) while 23 (36 %) were biopsied only. Thirty-five
(55 %) and 37 (58 %) patients were treated with chemotherapy and/or radiation, respectively. Thirty-five (55 %)
patients are alive (median follow-up, 12.2 years) while 29
(45 %) patients succumbed to their disease. A summary
of the clinical characteristics are shown in Table 1. Clinical characteristics of the Canadian cohort reflect those
described above and are available in Additional file 10:
Table S6.
Landscape of point mutations and fusion events in
thalamic tumours
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Table 1 Clinical characteristics of paediatric thalamic glioma
Characteristic

Number of patients

Male

34

Female

30

Alive

35

Dead

29

Low Grade

42

High Grade

22

Pilocytic

23

Diffuse

2

Anaplastic

9

Glioblastoma

11

Ganglioglioma

3

Low Grade, NOS

14

High Grade, NOS

2

GTR

11

STR

25

Partial Resection

5

Biopsy

12

Unknown

11

Treated

37

Not Treated

22

Unknown

5

Treated

35

Not Treated

26

Unknown

3

Median

9.25 years

Mean

8.77 ± 3.86 years

Median

6.43 years

Mean

8.78 ± 8.68 years

Sex

Outcome

Grade

Histology

Extent of Surgery

Radiation

Chemotherapy

Age at Diagnosis

Overall Survival

FGFR1N546K mutations were seen in 4 (6 %) tumour
samples. No FGFR1-TACC1, FGFR3-TACC3, other
BRAF or RAF fusions or MYBL1 alterations were detected in this cohort. Within the Canadian cohort,
H3K27M was identified in 5 (31 % of patients),
BRAFV600E in 3 (19 %) and KIAA1549-BRAF fusion
events in 3 (20 %) of 15 patients tested. No
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FGFR1N546K or FGFR1-TACC1, FGFR3-TACC3, other
BRAF or RAF fusions or MYBL1 alterations were detected within this cohort. Genetic aberration frequencies
based on histological grade can be seen in Additional
file 11: Table S7.
High grade histology and H3K27M are markers of poor
prognosis in thalamic glioma

Tumours diagnosed as high grade glioma (grades III and
IV) showed significantly worse overall survival when
compared to those defined as low grade (grade I and II)
in both the SickKids and Canadian cohorts (Additional
file 12: Figure S5). This trend was conserved with the removal of PA and GG from the low grade histology cohort (log-rank p = 0.0027). 5+ year overall survival for
patients diagnosed with a high grade glioma was 9.1 %
(2/22) as compared to 76.2 % (32/42) in tumours with
low grade histology. 9.1 % and 78.6 % of high and low
grade patients respectively were alive at the time the
study was completed. Likewise, the presence of
H3K27M was significantly related to worse patient outcome (Fig. 2a, log-rank p < 0.0001). Patients harbouring
the H3K27M mutation had a 5+ year overall survival of
6.3 % (1/16) as compared to 68.8 % (33/48) for H3WT
patients (Table 2). Similar results were observed in the
Canadian cohort (Fig. 2b, log-rank p = 0.0002). Of the 16
H3K27M positive cases, 5 and 11 were low and high
grade glioma, respectively. All 16 of these patients succumbed to their disease. No patient with a morphologically classic pilocytic astrocytoma harboured an H3K27M
mutation, suggestive of a minimum grade II histology in
NOS cases.
H3K27M is present in low grade thalamic glioma and
confers a negative prognosis

When separated based on histological grade, both
H3K27M and H3WT high grade glioma cases showed poor
prognosis (Fig. 2c), with tumours harbouring H3K27M having slightly worse outcome (log-rank p = 0.0109). Long
term survival (5+ years) in high grade cases was exclusively
seen in H3WT patients. Strikingly, H3K27M positive low
grade cases had significantly worse outcome than H3WT
low grade tumours (log-rank p < 0.0001), with all H3K27M
patients succumbing to their disease (Fig. 2d). Upon removal of PA and GG from the low grade cohort, the presence of H3K27M remained a predictor of a worse patient
outcome (log-rank p =0.0195). Interestingly, when
compared to high grade H3K27M glioma patients, patient survival was significantly longer for patients with
low grade glioma histology (median survival 1.44
[range, 0.52–13.66] and 0.76 [range, 0.12–1.52] years
for low grade versus high grade respectively, log-rank
p = 0.0361) suggesting that under-grading due to sampling error does not account for the finding of
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Sex
Histology
Cohort
H3K27M
H3G34R
H3G34V
BRAFV600E
FGFR1N546K
KIAA1549-BRAF

Low Grade
High Grade

Wild Type

Cohort

Female

Genetics

Male

Histology

Sex

FGFR1-TACC

Mutant
Insufficient
Quality/Material

Canadian

SickKids

Fig. 1 Genetic, molecular and clinical characteristics of paediatric thalamic glioma

H3K27M in low grade glioma. MRI review of available
cases showed no obvious differences within the low grade
H3K27M cases to suggest that a high grade tumour was
present. Importantly, of patients with low grade thalamic
gliomas and H3WT genotype, 89 % were alive at the completion of this study (median follow-up 12.2 years). Four
low grade H3WT cases succumbed to their disease, all of
which were WT for all aberrations tested in this study.
Taken together, the presence of low grade histology and
H3WT status resulted in the most favourable patient outcome, while high grade histology and H3K27M resulted in
the worst outcome (Fig. 2e). Low grade histology in the
presence of H3K27M as well as high grade H3WT cases
act intermediately. Similar clinical outcome in H3K27M
and H3WT cases were observed within the Canadian cohort (Additional file 13: Table S8).

B

Discovery Cohort
H3K27M

E

Validation Cohort
H3K27M

100

H 3W T

P e r c e n t S u r v iv a l

P e r c e n t S u r v iv a l

100

MAPK pathway activation via BRAF and FGFR1 hotspot
mutations or fusion events was detected in 28 (44 %) of
childhood thalamic gliomas. BRAFV600E was detected
in 2 and 8 high and low grade gliomas, respectively. Of
the 2 high grade patients with BRAFV600E, one patient
also harboured H3K27M and had poor survival
(1.43 years) in line with the H3K27M phenotype. Anecdotally, the patient with H3WT high grade glioma and
BRAFV600E is still alive and has a longer survival compared to most other high grade tumours (3.75 years
follow-up). In low grade gliomas, the presence of
BRAFV600E was associated with excellent overall survival (10.27 [range, 1.27–24.95] year median survival);
the only patient (1) deceased by the study endpoint was

50

p<0.0001

100

H 3W T

P e r c e n t S u r v iv a l

A

MAPK pathway activation is a marker of good prognosis
in thalamic glioma

50

L o w G ra d e + H 3 W T
L o w G ra d e + H 3 K 2 7 M

50

H ig h G r a d e + H 3 W T
H ig h G r a d e + H 3 K 2 7 M

p=0.0002
p<0.001

0

0

0

0

10

20

30

0

O v e ra ll S u r v iv a l (y e a r s )

15

0

10

20

30

O v e ra ll S u r v iv a l (y e a r s )

Low Grade Tumours

D
100

H3K27M
H 3W T

50

p=0.0109

P e r c e n t S u r v iv a l

P e r c e n t S u r v iv a l

100

10

O v e ra ll S u r v iv a l (y e a r s )

High Grade Tumours

C

5

H3K27M
H 3W T
50

p<0.0001
0

0
0

5

10

15

20

O v e ra ll S u r v iv a l (y e a r s )

25

0

10

20

30

O v e ra ll S u r v iv a l (y e a r s )

Fig. 2 H3K27M is a negative prognostic marker in paediatric thalamic glioma. SickKids cohort (a) and )(b) Canadian cohort were tested for
association between H3K27M-status and survival. Sample stratification based on histological grade showed H3K27M a significant prognostic
marker in high grade (c) and low grade (d). Histology and H3K27M status combined (e) revealed clinical disease stratification
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Table 2 Clinical characteristics of H3K27M and H3WT paediatric
thalamic glioma
Characteristic

Number of patients
H3WT

H3K27M

48

16

Male

28

6

Female

20

10

Alive

35

0

Dead

13

16

Low Grade

37

5

High Grade

11

11

Pilocytic

23

0

Diffuse

0

2

Anaplastic

6

3

Glioblastoma

5

6

Ganglioglioma

3

0

Low Grade, NOS

11

3

High Grade, NOS

0

2

GTR

11

0

STR

19

6

Partial Resection

3

2

Biopsy

7

5

Unknown

8

3

Treated

29

8

Not Treated

16

6

Unknown

3

2

Treated

29

6

Not Treated

17

9

Unknown

2

1

Median

9.02 years

10.50 year

Mean

8.24 ± 3.93 years

10.35 ± 3.23 years

Sex

Outcome

Histology

Grade

Extent of Surgery

Radiation

Chemotherapy

Age at Diagnosis

Overall Survival
Median

9.12 years

1.02 years

Mean

11.10 ± 8.69 years

1.81 ± 3.25 years

also H3K27M-positive as compared to 100 % 5-year survival of all other cases (Fig. 3a). BRAF fusion events were
exclusively seen in low grade tumours, were never associated with H3K27M and were associated with excellent
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long-term survival (5+ year survival of 78.6 % [11/14])
(Fig. 3b). All patients harbouring a BRAF fusion event
were alive upon completion of this study (mean followup 13.02 years). FGFR1 mutations were found in 6 % of
thalamic gliomas (5 % and 9 % of low and high grade tumours respectively). FGFR1 mutations were observed to
co-occur with H3K27M in two cases and as with
BRAFV600E, the H3K27M phenotype of poor survival
was observed. The FGFR1 positive, H3K27M negative
patients behaved in accordance to their histological
grade, with the grade IV case succumbing to the disease
in 1.71 years while the grade I surviving 25.46 years at
the time of last follow-up. FGFR1 mutations were mutually exclusive with BRAFV600E and BRAF fusion events
in this series. Overall, the presence of MAPK pathway
activation in the absence of H3K27M was related to robust patient survival (91 % 5-year survival), whereas in
the presence of H3K27M the prognosis remained poor
across all histological grades (Fig. 3c).
H3K27M status, extent of resection and histological grade
are independent predictors of patient survival in thalamic
glioma

To determine their relative predictive values, we performed univariate analysis of H3K27M, MAPK pathway activation, extent of surgical resection, adjuvant
therapy and histological grade. On univariate analysis
histological grade (high grade versus low grade, HR
9.905 [range 4.378–22.408], p < 0.0001), extent of resection (resection versus biopsy, HR 0.399 [range
0.191–0.831], p = 0.014) and H3K27M status (K27M
versus WT, HR 9.403 [range 4.253–20.788], p < 0.001)
and MAPK pathway activation (Activated versus WT,
HR 0.190 [range 0.072–0.500], p = 0.001 are predictive
markers of overall survival (Table 3). On multivariate
analysis, only H3K27M status (HR 6.945, p < 0.0001),
histologic grade (HR 7.721, p < 0.0001) and extent of
surgical resection (HR 0.325, p = 0.025) were significant independent predictors of patient survival.

Discussion
Thalamic tumours present a significant challenge for clinicians in terms of accurate diagnosis and an appropriate therapeutic approach. This study investigated the
prognostic potential of molecular alterations and clinical
factors in a concisely defined thalamic glioma cohort.
As expected, our results show the presence of
H3K27M mutations in 50 % of high grade paediatric
thalamic tumours [5, 20, 31, 33]. Interestingly, 12 % of
patients diagnosed with low grade thalamic tumours also
tested positive for H3K27M despite previous reports
suggesting it to be exclusive to high grade cases when
not located in the brainstem [31, 33]. Of note, two of
five low grade cases positive for H3K27M later
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A

B
100

P e r c e n t S u r v iv a l

P e r c e n t S u r v iv a l

100

B R A FV600E
BRAFV600E+H3K 27M
50
W ild T y p e
H3K27M

W ild T y p e
50

B R A F F u s io n

p<0.0001

P=0.2478

0

0
0

10

20

30

0

10

O v e ra ll S u r v iv a l (y e a r s )

20

30

O v e ra ll S u r v iv a l (y e a r s )

C
100

P e r c e n t S u r v iv a l

M A P K A c tiv a tio n
M A P K A c tiv a tio n + H 3 K 2 7 M
H3K27M
W ild T y p e
50

p<0.0001
0
0

10

20

30

O v e ra ll S u r v iv a l (y e a r s )

Fig. 3 MAPK pathway activation is a positive predictive marker. BRAFV600E in the absence of H3K27M in low grade tumours. a shows a survival
advantage. BRAF fusion events in low grade tumours. b shows robust survival. MAPK activation combined. c shows reveals a positive prognosis
throughout low and high grade tumours

transformed to high grade malignancies at the time of
second surgery, a rare occurrence in paediatric low
grade glioma and consistent with the diagnosis of secondary HGG [25]. While it is possible that these
H3K27M positive thalamic gliomas were under-graded
histologically based on sampling bias, the significant survival difference observed between low grade and high
grade H3K27M tumours supports the idea that these tumours were indeed distinct from their high grade counterparts. Further, there is a lack of any distinguishing
MRI characteristics to suggest under-grading in these
cases. Importantly, under the new World Health
Organization classifications published recently, these

tumours would be classified as diffuse midline glioma,
H3-K27M mutant, further supporting their unique
identity as compared to non-H3K27M low grade tumours [24].
Patients harbouring H3K27M showed significantly
worse overall survival when compared to H3WT cases.
Once separated based on histological grade, both low
and high grade tumours maintained a significantly worse
survival in the presence of H3K27M. Of note, high grade
thalamic tumours, regardless of H3K27M status, yielded
dismal survival with those harbouring the mutation succumbing to their disease in a slightly faster timeframe.
This result coincides with our previous work in DIPG

Table 3 Univariate and multivariate Cox analysis of genetic and clinical determinants of paediatric thalamic glioma
Variable

Univariate (95 % CI)

p value

Multivariate (95 % CI)

p value

Histology (HG vs. LG)

9.905 [4.378–22.408]

<0.0001

7.721 [2.437–24.461]

<0.0001

Surgery (resection vs. biopsy)

0.399 [0.191–0.831]

0.014

0.325 [0.122–0.869]

0.025

Chemo. (yes vs. no)

0.969 [0.441–2.127]

0.969

0.549 [0.213–1.416]

0.215

Rad. (yes vs. no)

1.048 [0.459–2.396]

0.911

0.898 [0.343–2.349]

0.827

H3K27M (mut. vs. WT)

9.403 [4.253–20.788]

<0.0001

6.945 [2.190–22.020]

<0.0001

MAPK Activation (mut. vs. WT)

0.190 [0.072–0.500]

0.001

0.385 [0.134–1.102]

0.075

LG low grade, HG high grade
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[5, 20], where we found H3K27M to be a negative prognostic marker in DIPG, albeit independent of tumour
histology. Previous research investigating the impact of
H3K27M on high grade adult midline tumours found a
correlation between H3K27M and poor survival in the
brainstem, but not the thalamus [1, 13]. Similar to this
study, in our cohort high grade histology was associated
with a poor outcome in both H3K27M and H3WT patients. However, in our cohort, several longer term survivors with H3WT high grade gliomas were present
making the overall survival slightly better for H3WT
patients. Work investigating paediatric glioblastoma
(Grade IV) identified H3K27M positive cases as
showing poor survival in midline cases including
those in the brainstem and thalamic regions, consistent with our findings [21].
The presence and effect of H3K27M mutations in low
grade malignancies on patient outcome has not previously been shown in malignancies outside the brainstem.
In this study, patients with low grade thalamic gliomas
had good overall survival with 79 % of patients alive
upon the completion of this study (mean follow-up
14.03 years), consistent with previous studies [3, 11, 15,
29, 30]. However, all 5 patients whose low grade gliomas
were positive for H3K27M succumbed to their disease,
with increased latency compared to high grade H3K27M
cases. These findings substantiate the knowledge that
H3K27M mutations do exist in low grade tumours and
that H3K27M status can supplement histological grading
in determining the clinical progression of the tumour.
Importantly, the poor survival of patients with H3K27M
low grade glioma suggests that they should be treated as
high grade glioma; receiving more aggressive adjuvant
therapies than would be typically given to low grade glioma patients.
MAPK pathway activation was detected in 44 % of patients. BRAFV600E was detected in 10 (16 %) of the
thalamic tumour samples, a slightly lower percentage
than previously reported [29, 30]. However, in these reports, the thalamus was grouped with all diencephalonbased structures, potentially altering the true prevalence.
Furthermore, this study identified the presence of
BRAFV600E mutations in 3 grade I malignancies for the
first time, in contrast with previous reports [11]. In the
absence of H3K27M, BRAFV600E cases were associated
with a good clinical outcome. Previously we reported
that low grade tumours having BRAFV600E were at a
higher risk for developing secondary high grade glioma
[25]. However, only 3 patients within this initial study
were identified as thalamic, of which one co-occurred
with H3K27M and another with CDKN2A deletion, potentially predisposing to tumour transformation. Furthermore, although the results here suggest robust
survival in our BRAFV600E cohort, our median follow-
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up was 10.27 years and it is possible that with longer latency these patients may develop high grade glioma.
Therefore, patients harboring low grade BRAFV600E tumours should be monitored closely post-treatment for
disease progression. In the presence of H3K27M,
BRAFV600E patients had an outcome similar to
BRAFWT, H3K27M-positive cases, suggesting that
H3K27M is the dominant prognostic indicator.
KIAA1549-BRAF fusion events were exclusive to low
grade thalamic glioma and were found in 39 % of tested
tumours. This percentage is similar to previous reports
in midline paediatric low grade glioma [11, 15]. However, it should be noted that these studies included nonthalamic locations, including the cerebellum, hypothalamus, optic pathway and brainstem. Patients with a
KIAA1549-BRAF fusion showed robust survival, with all
14 patients alive at the time this study was completed
(median follow-up: 11.55 years). FGFR1N546K was detected in 4 patients (6 %) and was seen in both low and
high grade cases. FGFR1N546K mutations have been
previously linked to decreased patient survival [3]. The
small number of patients harbouring this mutation in
this cohort means conclusions related to its prognostic
significance cannot be drawn. However, of the 4 FGFR1
mutated patients, the 2 also harbouring H3K27M
showed poor survival in accordance with the H3K27M
phenotype. Alternately, FGFR1 mutated patients without
H3K27M behaved in accordance with their histological
grade, suggesting that histology and H3K27M status are
the main phenotypic contributors in these cases. We did
not identify FGFR1-TACC1 or FGFR3-TACC3 fusions in
our cohort as described in [34].
The presence of MAPK pathway activation was found
in 28 patients within our cohort, 89 % of which were
low grade glioma. Importantly, of the 3 high grade cases
with MAPK activation, 2 were also H3K27M and behaved in accordance with the H3K27M phenotype. The
remaining high grade, MAPK activated sample shows a
prolonged survival in comparison to other high grade
tumours (3.75 years) and was alive upon the completion
of this study. In low grade tumours, the presence of
MAPK activation, regardless of fusion or hotspot mutation event was related to prolonged survival. Taken together, H3K27M and MAPK pathway activation
effectively stratifies thalamic tumours into survival
groups. MAPK pathway activation in the absence of
H3K27M confers long-term survival across the entire
cohort irrespective of tumour histology. Tumours wild
type for the genetic targets tested here behave in close
accordance with their histological grade. Further testing
is required to identify additional genetic marks capable
of further stratifying this group. Importantly, it must be
recognized that a limitation of this study in respect to
MAPK activation is the inclusion of pilocytic
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astrocytoma and ganglioglioma within the low grade
histology category. This saturation of circumscribed and
non-invasive lesions positive for MAPK activation may
partially explain the robust survival seen. However, in
the case of thalamic tumours, the finding appear consistent across histological grades and as such, remain an important clinical predictor of patient outcome. Lastly,
tumours harbouring H3K27M, regardless of histology or
MAPK activation show dismal survival. In this respect,
H3K27M is one of the most critical factors in predicting
patient outcome in thalamic glioma cases and must be
considered equally important as tumour histology in primary prognostic categorization.

Conclusions
In summary, this study supports the inclusion of targeted H3K27M and MAPK activation testing via clinically approved methodology in all paediatric midline
tumours regardless of histological grade. This helps provide an accurate prediction of patient outcome and appropriate therapeutic options. Further, we provide fully
optimized and cost-effective strategies to targeting these
aberrations in a clinical setting.
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